HCW Biologics (HCWB) Return on Capital Employed (2021 - 2025)
HCW Biologics' (HCWB) quarterly Return on Capital Employed came in at 336.32% in Q4 2025, down 272700.0% YoY from N/an in Q4 2024, and up 91.01% on a QoQ basis from 3739.81% in Q3 2025.
HCW Biologics (HCWB) Return on Capital Employed (2021 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 5 years of Return on Capital Employed data on file, last reported at 336.32% in Q4 2025.
- Quarterly Return on Capital Employed fell 272700.0% year-over-year to 336.32% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 336.32% (down 272700.0% YoY) and the FY2025 annual result came in at 208.41%, down 1181616.0% from the prior year.
- Return on Capital Employed rose to 336.32% in Q4 2025, from 3739.81% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2390.68% in Q4 2024 to a low of 3739.81% in Q3 2025.
- A 5-year average of 315.3% and a median of 49.28% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 250097 bps — and 2025, when it slumped 483854 bps.
- Tracing HCWB's Return on Capital Employed over 5 years: stood at 25.4% in 2021, then fell by 29 bps to 32.69% in 2022, then tumbled by 237 bps to 110.29% in 2023, then jumped by 2268 bps to 2390.68% in 2024, then tumbled by 114 bps to 336.32% in 2025.
- The last three Return on Capital Employed figures came in at 336.32% (Q4 2025), 3739.81% (Q3 2025), and 1631.83% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | -205.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -336.32% |
| Sep 30, 2025 | -3,739.81% |
| Jun 30, 2025 | -1,631.83% |
| Mar 31, 2025 | -2,139.05% |
| Dec 31, 2024 | 2,390.68% |
| Sep 30, 2024 | 1,098.72% |
| Jun 30, 2024 | -711.89% |
| Mar 31, 2024 | -173.43% |
| Dec 31, 2023 | -110.29% |
| Sep 30, 2023 | -64.16% |
| Jun 30, 2023 | -52.90% |
| Mar 31, 2023 | -45.65% |
| Dec 31, 2022 | -32.69% |
| Sep 30, 2022 | -26.60% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -23.29% |
| Dec 31, 2021 | -25.40% |
| Sep 30, 2021 | -25.35% |